Efficacy and Safety of Lenvatinib Plus Pembrolizumab for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 -Exposed Participants
This study will evaluate the safety and efficacy of combination therapy of lenvatinib (E7080/MK-7902) and pembrolizumab following approximately 2 years of pembrolizumab therapy and approximately 2 years or more lenvatinib therapy